Diabetic Eye Disease News and Research

RSS

Diabetic eye disease refers to a group of eye problems that people with diabetes may face as a complication of diabetes. All can cause severe vision loss or even blindness. Diabetic eye disease may include, diabetic retinopathy — damage to the blood vessels in the retina, Cataract—clouding of the eye's lens, glaucoma—increase in fluid pressure inside the eye that leads to optic nerve damage and loss of vision. A person with diabetes is nearly twice as likely to get glaucoma as other adults.

Study reveals limitations of large language models in medical diagnostics

Artificial intelligence (AI) is rapidly transforming healthcare. AI systems can now detect diabetic eye disease from retinal photos and analyze CT images for signs of early-stage lung cancers and stroke.

16 Mar 2026

Everday diabetes medicine linked to less progression of age-related macular degeneration

Doctors have found that metformin, an everyday medicine for diabetes, is associated with less progression of age-related macular degeneration (AMD), the commonest cause of blindness in western countries.

3 Feb 2026

New platform enables unbiased evaluation of AI algorithms for diabetic eye screening

Researchers have developed the world's first real-world head-to-head testing platform to determine whether commercial artificial intelligence (AI) algorithms are fit for NHS use to detect disease in a fair, equitable, transparent and trustworthy way, using diabetic eye disease as the first example.

24 Nov 2025

Live retinal imaging uncovers early signs of diabetic eye disease

A new method of taking microscopic images of a live mouse's retina through the eye allows to record the reaction of brain cells to disease and treatment.

6 Oct 2025

Exonate plans 'CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407.

29 Jul 2025

Affordable HIV drug shows promise in improving vision for diabetic eye disease

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more effectively and a much lower cost than many existing treatments, an initial clinical trial suggests.

27 May 2025

Low blood sugar linked to retinal damage in diabetic eye disease

In a new National Institutes of Health-funded study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers say they have determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier, an important boundary that regulates the flow of nutrients, waste and water in and out of the retina.

6 May 2025

Research highlights gender and age differences in eye gene therapy responses

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found.

10 Feb 2025

Johns Hopkins study offers new hope for wet AMD patients

A new study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet age-related macular degeneration (or "wet" AMD) fail to have vision improvement with treatment, but also how an experimental drug could be used with existing wet AMD treatments to save vision.

4 Nov 2024

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director. Rafiq brings extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses.

28 May 2024

Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation

Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming Phase IIb study following successful Phase Ib/IIa study.

12 Mar 2024

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.

5 Mar 2024

AI exam boosts diabetic eye screening rates in youth

A Johns Hopkins Children's Center study of children and youth with diabetes concludes that so-called autonomous artificial intelligence (AI) diabetic eye exams significantly increase completion rates of screenings designed to prevent potentially blinding diabetes eye diseases (DED).

11 Jan 2024

Can AI predict diabetic eye disease progression?

"DeepDR Plus," a deep learning system, accurately predicts diabetic retinopathy progression up to five years using fundus images, offering potential for personalized screening and management in diabetic patients.

7 Jan 2024

Two-year diabetic eye screening could lead to treatment delays and sight loss

Extending the annual screen to two years for people in England considered at low risk of diabetic eye disease could lead to critical treatment delays and sight loss, according to research led by St George's, University of London and Moorfields Eye Hospital NHS Foundation Trust and involving Kingston University, London researchers and academics.

31 Oct 2023

Study: Extending diabetic eye screen to 2 years could risk critical treatment delays and sight loss

Extending the annual screen by a year for people in England considered to be at low risk of diabetic eye disease (diabetic retinopathy) could risk critical treatment delays and/or sight loss, suggests a large, real world data study, published online in the British Journal of Ophthalmology.

25 Oct 2023

Study reveals why hypoglycemic episodes worsen diabetic retinopathy

People with diabetes who experience periods of low blood sugar — a common occurrence in those new to blood sugar management — are more likely to have worsening diabetic eye disease.

26 Jan 2023

New project to deploy AI technology for detecting sight-threatening diabetic eye disease

St George's, University of London and Moorfields Eye Hospital NHS Foundation Trust are leading a half a million pound project on artificial intelligence (AI), funded by NHSX and the Health Foundation, and enabled by the National Institute for Health Research.

22 Oct 2021

Youth-onset type 2 diabetes is more aggressive and difficult to control, study shows

People with type 2 diabetes diagnosed during youth have a high risk of developing complications at early ages and have a greater chance of multiple complications within 15 years after diagnosis.

28 Jul 2021

New biomarkers in the eyes could unlock the key to management of diabetic retinopathy

New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.

26 Jul 2021